Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Adicet Bio, Inc. (TORC)
|
Add to portfolio |
|
|
|
| Price: |
$16.99
| | Metrics |
| OS: |
43.1
|
M
| |
-53
|
% ROE
|
| Market cap: |
$732
|
M
| |
-320
|
% ROIC
|
|
Net cash:
|
$205
|
M
| |
$4.77
|
per share
|
|
EV:
|
$526
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($141)
|
M
| |
|
|
| EPS |
($2.95)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.0 | 71.2 | 0.0 | 48.9 | 0.0 | 1.0 | 8.2 | 0.0 |
| Revenue growth | | 45.6% | | | -100.0% | -87.8% | | |
| Cost of goods sold | 0.0 | 97.5 | 0.0 | 71.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | -26.3 | 0.0 | -22.2 | 0.0 | 1.0 | 8.2 | 0.0 |
| Gross margin | | -36.9% | | -45.4% | | 100.0% | 100.0% | |
| Selling, general and administrative | 97.5 | | 71.2 | | 57.1 | | | |
| Research and development | | | | | | 23.7 | 14.7 | 16.8 |
| General and administrative | | 26.3 | | 22.2 | | 8.7 | 8.4 | 2.0 |
| EBIT | -76.1 | -72.6 | -62.3 | -61.4 | -40.2 | -31.4 | -15.0 | -18.9 |
| EBIT margin | | -101.8% | | -125.5% | | -3154.6% | -182.9% | |
| Pre-tax income | -69.8 | -69.8 | -62.1 | -62.1 | -39.5 | -28.1 | -9.9 | -33.8 |
| Income taxes | 0.0 | 0.0 | -0.1 | -0.1 | -2.8 | 0.0 | -0.6 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.2% | 0.2% | 7.1% | | 6.0% | 0.0% |
| Net income | -69.8 | -69.8 | -62.0 | -62.0 | -36.7 | -28.1 | -9.3 | -33.8 |
| Net margin | | -98.0% | | -126.7% | | -2827.9% | -113.7% | |
| |
| Diluted EPS | ($1.70) | ($1.70) | ($2.00) | ($2.00) | ($5.01) | ($13.15) | ($4.78) | ($8.42) |
| Shares outstanding (diluted) | 41.1 | 41.1 | 31.0 | 31.0 | 7.3 | 2.1 | 1.9 | 4.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|